Hemab Therapeutics raises $135m for prophylactic treatments for bleeding and thrombotic disorders
Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing prophylactic treatments for underserved bleeding and thrombotic ... Read More
Modus Therapeutics secures $15.7m for sickle cell disease drug development
Modus Therapeutics, a Swedish biotech firm specializing in sickle cell disease therapies, has successfully raised SEK 140 million ($15.76 million) in a funding round spearheaded ... Read More